Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 ...

For many, Novavax is #1 – the one and only COVID vaccine they would consider. This enthusiasm for Novavax isn’t new. As far back as 2022, news reports described a kind of Novavax fan club – a term ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

U.S. regulators have cleared a third updated Covid-19 vaccine for this fall, shots made by Novavax. Already, Pfizer and Moderna are shipping shots modified to better match more recent strains of ...

logo of US biotech company Novavax. Novavax’s vaccine targets the JN.1 COVID-19 variant, which was the dominant strain circulating in the U.S. earlier this year but now makes up less than 1% of ...

The newly approved vaccine targets multiple circulating variants, promising enhanced protection and availability across ...

It may seem like a similar story for investors but Novavax has obtained approval for a COVID-19 vaccine -- yet again. On Aug. 30, the healthcare company announced that the Food and Drug ...

Novavax Inc. closed $10.66 short of its 52-week high ($23.86), which the company reached on June 6th. Supported by ...

Novavax Inc. closed $11.08 short of its 52-week high ($23.86), which the company achieved on June 6th.

Novavax stock rose on its strong earnings, though sales came in light and the company cut its outlook. Is NVAX stock a buy or a sell? Novavax, Inc. (Nasdaq: NVAX), a global company advancing ...